Michael Rachlin leads the life sciences Valuation & Financial Advisory Services practice, specializing in assisting clients in the biopharmaceutical, medical technology and cannabis industries evaluate transaction opportunities and larger growth-related initiatives, as well as valuation, deal modeling and strategic alternatives. Mr. Rachlin has fifteen years of experience advising life sciences clients through their most critical transaction and transformation challenges.
Mr. Rachlin provides complex financial modeling, valuation and financial advisory services for a variety of strategic planning, acquisition planning, litigation, and financial and tax reporting purposes. He has experience delivering customized solutions across the M&A lifecycle, including target screening, diligence, structuring, purchase accounting and post-merger integration. He designs and delivers custom solutions that address the financial needs of both large and middle-market life sciences organizations.
Prior to joining FTI Consulting, Mr. Rachlin was a senior leader at Deloitte Transactions & Business Analytics, LLP, where he oversaw a range of transaction and financial advisory services for the firm’s middle-market life sciences segment, including strategy, planning, go-to-market and delivery.
Mr. Rachlin is an adjunct professor at Brooklyn Law School where he teaches financial modeling, valuation and finance and previously sat on the Finance Committee at BioNJ, where he focused on financial topics for pharmaceutical companies.